Pharmaceuticals

Global Primary Myelofibrosis Industry Trends: Where the Market Is Headed by 2029

November 14, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Primary Myelofibrosis Market Expected To Become By 2029 Compared With Its 2025 Level?

The primary myelofibrosis market has experienced significant growth in recent years. It is anticipated to increase from $0.79 billion in 2024 to $0.84 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.4%. This historical expansion can be attributed to factors such as improved disease recognition among medical professionals, the increasing application of JAK inhibitors, enhanced diagnostic capabilities and genetic testing, greater availability of hematology specialists for patients, and a rise in clinical trial initiatives.

The primary myelofibrosis market is projected to experience substantial growth in the upcoming years. This market is anticipated to expand, reaching $1.07 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.2%. The expected growth during this forecast period stems from factors such as an expanding pipeline of innovative therapies, a rising demand for treatments that modify the disease, increasing prevalence within aging demographics, a growing emphasis on combination treatment strategies, and heightened investment from pharmaceutical and biotech enterprises. Significant trends for the forecast duration encompass progress in targeted drug development, the incorporation of next-generation sequencing (ngs) in diagnostic procedures, technology-enabled monitoring solutions, advancements in combination therapy protocols, and improvements in bone marrow fibrosis imaging techniques.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

What Are The Key Drivers Of Growth In The Primary Myelofibrosis Market?

The projected increase in the occurrence of myelofibrosis is anticipated to drive the expansion of the primary myelofibrosis market moving forward. Myelofibrosis is a rare form of bone marrow cancer that interferes with the body’s normal generation of blood cells, resulting in extensive scarring within the bone marrow, which then causes severe anemia, weakness, fatigue, and an enlarged spleen. The heightened prevalence of myelofibrosis is primarily attributed to the world’s aging population, given that the condition typically impacts individuals over the age of 60, and extended life expectancies are leading to a greater number of diagnosed cases. This rising prevalence of myelofibrosis enhances the management of primary myelofibrosis by fostering research, improving early detection, expanding therapeutic options, and advocating for better clinical guidelines and specialized medical attention. For instance, in November 2024, a report published by the National Institute for Health and Care Excellence, an independent executive non-departmental public body based in the UK, stated that myelofibrosis has a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. Therefore, the growing prevalence of myelofibrosis is a significant factor boosting the primary myelofibrosis market.

What Are The Emerging Segments Gaining Attention In The Primary Myelofibrosis Market?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

What Trends Are Expected To Drive The Primary Myelofibrosis Market?

Leading companies in the primary myelofibrosis market are concentrating on developing innovative solutions, such as Janus kinase 2 inhibiting tablets, to enhance symptom control and slow the advancement of the disease. Janus kinase 2 (JAK2) inhibiting tablets are oral drugs that obstruct the action of the JAK2 enzyme, which plays a role in the irregular signaling pathways causing excessive blood cell production in primary myelofibrosis. These tablets contribute to reducing spleen size, alleviating symptoms of fatigue and bone pain, and decelerating disease progression. For example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, introduced Omjjara (momelotinib) as a novel treatment for myelofibrosis. It has been approved by South Korea’s Ministry of Food and Drug Safety and is designated for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also suffer from moderate to severe anemia. Omjjara is an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), thereby effectively addressing symptoms like anemia, an enlarged spleen, and fatigue. Its approval is substantiated by clinical trial data that demonstrated notable improvements in anemia, spleen size, and overall symptoms compared to existing treatments.

Which Leading Players Are Enhancing Their Primary Myelofibrosis Market Presence Worldwide?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Primary Myelofibrosis Market?

North America was the largest region in the primary myelofibrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Primary Myelofibrosis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2025, By The Business Research Company

Myelodysplastic Syndrome Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795